BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 25819732)

  • 21. The tumor marker score is an independent predictor of survival in patients with recurrent hepatocellular carcinoma.
    Okamura Y; Ashida R; Ito T; Sugiura T; Mori K; Uesaka K
    Surg Today; 2015 Dec; 45(12):1513-20. PubMed ID: 25527455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigation of histological vascular invasion from preoperative evaluation in patients with hepatocellular carcinoma who underwent living donor liver transplantation.
    Sakai K; Okajima H; Koshino K; Suzuki T; Nobori S; Matsuyama M; Ushigome H; Ochiai T; Yoshimura N
    Transplant Proc; 2012 Mar; 44(2):409-11. PubMed ID: 22410029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New Pathologic Stratification of Microvascular Invasion in Hepatocellular Carcinoma: Predicting Prognosis After Living-donor Liver Transplantation.
    Iguchi T; Shirabe K; Aishima S; Wang H; Fujita N; Ninomiya M; Yamashita Y; Ikegami T; Uchiyama H; Yoshizumi T; Oda Y; Maehara Y
    Transplantation; 2015 Jun; 99(6):1236-42. PubMed ID: 25427164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Study on the value of serum des-γ-carboxy prothrombin in predicting hepatocellular carcinoma recurrence after liver transplantation].
    Xu Y; Wang PX; Cheng JW; Huang XW; Zhou J; Fan J; Yang XR
    Zhonghua Gan Zang Bing Za Zhi; 2020 Nov; 28(11):918-923. PubMed ID: 33256276
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparative evaluation of expanded criteria for patients with hepatocellular carcinoma beyond the Milan criteria undergoing living-related donor liver transplantation.
    Shirabe K; Taketomi A; Morita K; Soejima Y; Uchiyama H; Kayashima H; Ninomiya M; Toshima T; Maehara Y
    Clin Transplant; 2011; 25(5):E491-8. PubMed ID: 21518000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Living-donor liver transplantation associated with higher incidence of hepatocellular carcinoma recurrence than deceased-donor liver transplantation.
    Park MS; Lee KW; Suh SW; You T; Choi Y; Kim H; Hong G; Yi NJ; Kwon CH; Joh JW; Lee SK; Suh KS
    Transplantation; 2014 Jan; 97(1):71-7. PubMed ID: 24056623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary versus salvage living donor liver transplantation for patients with hepatocellular carcinoma: impact of microvascular invasion on survival.
    Moon JI; Kwon CH; Joh JW; Choi GS; Jung GO; Kim JM; Shin M; Choi SJ; Kim SJ; Lee SK
    Transplant Proc; 2012 Mar; 44(2):487-93. PubMed ID: 22410053
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Time of hepatocellular carcinoma recurrence after liver resection and alpha-fetoprotein are important prognostic factors for salvage liver transplantation.
    Lee S; Hyuck David Kwon C; Man Kim J; Joh JW; Woon Paik S; Kim BW; Wang HJ; Lee KW; Suh KS; Lee SK
    Liver Transpl; 2014 Sep; 20(9):1057-63. PubMed ID: 24862741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of loco regional treatments before living donor liver transplantation on overall survival and recurrence-free survival in South Korean patients with hepatocellular carcinoma.
    Na GH; Kim EY; Hong TH; You YK; Kim DG
    HPB (Oxford); 2016 Jan; 18(1):98-106. PubMed ID: 26776857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development and Applicability of the A-P 200 Criteria for Liver Transplantation for Hepatocellular Carcinoma.
    Yang K; Lee TB; Choi BH; Park YM; Ryu JH; Joo DJ; Chu CW
    Transplant Proc; 2016 Dec; 48(10):3317-3322. PubMed ID: 27931576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Significance of Preoperative Hepatocellular Carcinoma With High
    Yamao T; Yamashita YI; Imai K; Umezaki N; Tsukamoto M; Kitano Y; Arima K; Miyata T; Nakagawa S; Okabe H; Hayashi H; Chikamoto A; Ishiko T; Baba H
    Anticancer Res; 2019 Feb; 39(2):883-889. PubMed ID: 30711971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation.
    Ito T; Takada Y; Ueda M; Haga H; Maetani Y; Oike F; Ogawa K; Sakamoto S; Ogura Y; Egawa H; Tanaka K; Uemoto S
    Liver Transpl; 2007 Dec; 13(12):1637-44. PubMed ID: 18044766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of the preoperative des-gamma-carboxy prothrombin level on prognosis after hepatectomy for hepatocellular carcinoma meeting the Milan criteria.
    Sakaguchi T; Suzuki S; Morita Y; Oishi K; Suzuki A; Fukumoto K; Inaba K; Nakamura S; Konno H
    Surg Today; 2010 Jul; 40(7):638-45. PubMed ID: 20582515
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Usefulness of the Kyoto criteria as expanded selection criteria for liver transplantation for hepatocellular carcinoma.
    Kaido T; Ogawa K; Mori A; Fujimoto Y; Ito T; Tomiyama K; Takada Y; Uemoto S
    Surgery; 2013 Nov; 154(5):1053-60. PubMed ID: 24074704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors affecting recurrence and survival after living donor liver transplantation for hepatocellular carcinoma.
    Abdel-Wahab M; Sultan AM; Fathy OM; Salah T; Elshobary MM; Elghawalby NA; Yassen AM; Elsarraf WM; Elsaadany MF; Zalatah K
    Hepatogastroenterology; 2013; 60(128):1847-53. PubMed ID: 24719918
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic impact of surgery and radiofrequency ablation on single nodular HCC ⩽5 cm: Cohort study based on serum HCC markers.
    Ueno M; Hayami S; Shigekawa Y; Kawai M; Hirono S; Okada K; Tamai H; Shingaki N; Mori Y; Ichinose M; Yamaue H
    J Hepatol; 2015 Dec; 63(6):1352-9. PubMed ID: 26212030
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
    Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
    Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
    Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW
    J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic factors affecting survival after recurrence in adult living donor liver transplantation for hepatocellular carcinoma.
    Shin WY; Suh KS; Lee HW; Kim J; Kim T; Yi NJ; Lee KU
    Liver Transpl; 2010 May; 16(5):678-84. PubMed ID: 20440777
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of living-donor liver transplantation in surgical treatment for hepatocellular carcinoma.
    Yokoi H; Isaji S; Yamagiwa K; Tabata M; Nemoto A; Sakurai H; Usui M; Uemoto S
    J Hepatobiliary Pancreat Surg; 2006; 13(2):123-30. PubMed ID: 16547673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.